Trials / Completed
CompletedNCT02489838
Lung Dose in Patients Treated With Yttrium-90 for Hepatocellular Carcinoma
Analysis of Lung Dose Using Volumetric Analysis in Patients Treated With Yttrium-90 Microsphere Radioembolization for Hepatocellular Carcinoma
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 56 (actual)
- Sponsor
- Alan Katz · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To Calculate the amount radiation the lung receives in patients receiving Yttrium-90 for Liver Cancer.
Detailed description
To calculate the delivered lung dose using quantitative volumetric analysis in a cohort of patients with unresectable hepatocellular carcinoma who undergo selective internal radiation therapy (SIRT) with Yttrium-90 glass microspheres (TheraSphere®)-and compare this analysis to the lung dose estimated by established criteria. In addition, this study, will summarize the pre and post-treatment clinical data to describe the URMC Y-90 experience.
Conditions
Timeline
- Start date
- 2012-02-03
- Primary completion
- 2019-08-07
- Completion
- 2019-08-07
- First posted
- 2015-07-03
- Last updated
- 2020-06-11
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02489838. Inclusion in this directory is not an endorsement.